FDA Warning Letter

Regulatory Event

On July 2, 2026, FDA issued Warning Letter 320-26-99 to International Medication Systems Limited, a South El Monte, California manufacturer of both active pharmaceutical ingredient (API) and aseptically filled sterile injectable drug products, following an inspection conducted December 9 to 19, 2025. The letter documents a too-numerous-to-count (TNTC) microbial finding with confluent bacterial growth and insect larvae recovered from a viable air monitoring plate in the firm’s ISO 5 aseptic filling area, an investigation that attributed the finding to an unsubstantiated insect-infiltration hypothesis, a quality unit that released the implicated lot anyway, and a recall that occurred only after FDA directly recommended it in a March 26, 2026 teleconference. Epinephrine injection USP 0.1 mg/mL, lot EA038A5, was voluntarily recalled on April 1, 2026 for lack of sterility assurance — roughly three and a half months after the inspection closed and more than two months after the firm’s own January 15, 2026 written response defended the release decision.

The primary citation, 21 CFR 211.192, requires that firms thoroughly investigate any unexplained discrepancy or failure of a batch to meet its specifications, whether or not the batch has already been distributed. What FDA found instead was a viable air plate adjacent to the filling equipment in the ISO 5 zone showing TNTC confluent bacterial growth and insect larvae, with a personnel monitoring plate in the adjacent ISO 7 area yielding the same result on the same day. The firm’s investigation concluded that sealed monitoring plates had somehow been infiltrated by insects — a hypothesis unsupported by any documented plate defect or sampling error, and inconsistent with the firm’s own written procedures requiring pre-use plate inspection and strict aseptic handling during sampling. The growth media batch passed negative control testing, which should have ruled out a reagent-based explanation but did not change the firm’s conclusion. Based on this unsupported theory, the deviation was scored as low risk and the quality unit released lot EA038A5. When challenged, the firm revised its explanation to “post-exposure adventitious contamination external to the filling suite,” relying on mostly acceptable environmental monitoring results elsewhere that day. FDA’s rejection of this reasoning was direct: two severe, simultaneous contamination events in adjacent classified rooms describe a systemic breakdown in contamination control, not two isolated incidents, and the firm’s decision to implement no corrective action compounded rather than resolved the deficiency.

What the Record Documents

This pattern — a root-cause conclusion that lacks any specific, assignable technical basis, followed by release of the batch anyway — is the same investigational failure mode FDA has cited across sterile manufacturing enforcement for over a decade. At Ben Venue Laboratories’ Bedford, Ohio facility, FDA’s 2011 findings centered on a firm that failed to trend recurring environmental isolates and statistically derive its alert and action levels, allowing rising bioburden to go uninvestigated for 14 consecutive months before the site voluntarily ceased sterile manufacturing altogether. The common thread between Bedford and South El Monte is not the specific organism or root-cause narrative; it is a quality system that treats anomalous contamination signals as explainable noise rather than as data requiring rigorous, scientifically supported investigation under 21 CFR 211.192. That pattern is reinforced by the firm’s own history: between March 2021 and March 2026 the firm filed three field alert reports for contamination issues affecting sterile drug products, and since December 2023 it has received more than 90 customer complaints, many involving container-closure deficiencies such as glass breakage and vial cracking, with many investigations closed without an identified root cause. A single unexplained TNTC event might be an isolated failure. A five-year pattern of contamination-related field alerts and complaints closed without root cause is a quality system that is not functioning as designed.

The second major citation combines 21 CFR 211.42(c)(10) and 211.113(b): failure to perform operations within specifically defined and controlled aseptic processing areas, and failure to establish procedures designed to prevent microbiological contamination and validate aseptic processes. FDA’s finding here is unusually pointed — the firm describes its aseptic filling lines as restricted access barrier systems (RABS), but FDA determined the equipment lacks fundamental RABS design elements entirely, meaning the lines cannot properly be categorized as RABS at all. A true RABS is engineered specifically to minimize or eliminate direct gowned-personnel intervention into the ISO 5 critical zone during batch manufacturing. What FDA observed instead was an operator standing within the ISO 5 area itself, manually cutting open numerous stopper bags per batch and transferring stoppers with a scoop — a repeated, manually intensive critical intervention performed without any environmental monitoring in that specific area to evaluate its impact. Compounding this, the firm’s smoke studies intended to verify unidirectional airflow in the critical zone were fundamentally flawed in wand placement and movement, precluding any meaningful assessment of whether first air over the exposed product path was actually being maintained. In response, the firm added one new monitoring location, asserted without adequate study design that operator movement had “no impact” on unidirectional airflow, and proposed a two-year facility upgrade plan. FDA rejected this as inadequate because it does not address the immediate, ongoing risk created by extensive manual intervention inside the critical processing zone today — a two-year roadmap does not substitute for controlling present-tense contamination risk.

Technical and Quality Context

The third citation, 21 CFR 211.63, addresses equipment design, size, and location suitable for its intended use, cleaning, and maintenance. Investigators found gross contamination in a water storage tank feeding a downstream water system used for cleaning drug manufacturing equipment: interior surfaces coated in dark-colored plaques, pipe repairs made with sealant material, and threaded connections using seal tape in place of sanitary fittings. The firm’s response characterized the plaques as biofilm resulting from ambient light exposure enabling photosynthetic growth — describing it as “predictable and environmentally normal” — and pointed to passing downstream test results as evidence of no quality impact, with tank cleaning as the sole corrective action. FDA’s rejection of this logic mirrors the letter’s own guidance on sterility testing: a passing test result at one point in a system does not establish control of a source that has become an active bioburden reservoir upstream of it. A source tank engineered and maintained to prevent unchecked biological growth is a design requirement, not something a downstream specification result can retroactively validate.

Together, these three citations describe a quality unit that is not exercising the authority CGMP requires it to hold — a conclusion FDA states explicitly in the letter’s Quality Unit Authority section, directing executive management to assess global manufacturing operations. For companies operating sterile injectable and API manufacturing under the same roof, the practical lesson is that contamination investigations, aseptic process design claims, and utility system qualification cannot be evaluated as separate silos; FDA is reading them, as it did here, as evidence of one underlying quality culture. XGene’s contamination control and Chemistry, Manufacturing, and Controls (CMC) remediation practice works with sterile manufacturers to build the kind of six-system CGMP assessment FDA recommends in this letter — quality, facilities and equipment, materials, production, packaging, and laboratory controls — paired with investigation frameworks that require a specific, assignable root cause before any contamination event can be closed as low risk.

Decision Relevance

For sterile injectable manufacturers, the lesson from South El Monte is threefold. First, an investigation conclusion that cannot identify a specific, assignable cause is not a completed investigation under 21 CFR 211.192, regardless of how the risk is subsequently characterized. Second, calling an aseptic line a RABS does not make it one; FDA evaluates the actual engineering controls that eliminate critical-zone interventions, not the label applied to the equipment. Third, a passing test result — whether a sterility test or a downstream water specification — cannot substitute for control of the system that produced the sample, a principle this letter states explicitly and one that governs sterility assurance decisions a quality unit makes.